Preclinical studies suggest that BPC-157 promotes healing of muscles, ligaments, tendons, and blood vessels, while also regulating inflammatory and oxidative stress responses without hormonal action
Conclusion Concerns about a potential pancreatic cancer signal with GLP-1 therapy originated from early reports and limited datasets
The most common side-effects seen with acarbose are mild-to-moderate gastrointestinal (GI) side-effects, including flatulence, diarrhoea and abdominal distension
doi: 10.1016/j.jcjd.2020.04.001
Their analysis follows a March 2024 report from the Congressional Budget Office (CBO) which found that at its current costranging from $1,000 to $1,300 for a four-week supplyMedicare will not be able to sustainably cover semaglutide
Similar medications in the GLP-1 class are known to cause symptoms such as: Nausea Bloating Gas Vomiting Heartburn Some research has also identified rare but more serious risks associated with GLP-1 medications, including pancreatitis, gallbladder disease, and gastrointestinal complications.[10] Because retatrutide is still being studied, researchers are continuing to evaluate its long-term safety profile